Finance

Lists
023910:KOSDAQ
Dai Han Pharm Co Ltd
â‚©27,150.00
-0.37%
(-100.00) 1D
Sep 4, 3:30:30 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 023910...
Open
â‚©27,250
High
â‚©27,350
Low
â‚©26,950
Mkt. cap
162.90B
Avg. vol.
8.54K
Volume
1.97K
Dividend
3.68%
Quarterly dividend
â‚©250
Ex-dividend date
Dec 27, 2023
P/E ratio
5.80
52-wk high
â‚©31,700
52-wk low
â‚©24,000
EPS
â‚©4,682
Shares outstanding
6.00M
No. of employees
768
Open
â‚©27,250
High
â‚©27,350
Low
â‚©26,950
Mkt. cap
162.90B
Avg. vol.
8.54K
Volume
1.97K
Dividend
3.68%
Quarterly dividend
â‚©250
Ex-dividend date
Dec 27, 2023
P/E ratio
5.80
52-wk high
â‚©31,700
52-wk low
â‚©24,000
EPS
â‚©4,682
Shares outstanding
6.00M
No. of employees
768
About Dai Han Pharm Co Ltd
CEO-
Employees768
Founded1945
Headquarters-
SectorPharmaceutical industry
Websitedaihan.com
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
56.17B
51.06B
52.71B
56.61B
Cost of goods sold
37.79B
38.11B
36.96B
39.97B
Cost of revenue
37.79B
38.11B
36.96B
39.97B
Research and development expenses
432.31M
614.41M
383.15M
312.68M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.09B
8.37B
7.33B
7.94B
Operating expense
7.75B
9.38B
7.89B
8.56B
Total operating expenses
45.54B
47.49B
44.85B
48.53B
Operating income
10.64B
3.57B
7.86B
8.08B
Other non operating income
-12.03M
16.84M
6.23M
-124.21M
EBT including unusual items
11.23B
4.17B
8.79B
8.74B
EBT excluding unusual items
11.26B
4.18B
8.87B
8.75B
Income tax expense
2.52B
-903.43M
1.81B
1.99B
Effective tax rate
22.39%
-21.65%
20.57%
22.75%
Other operating expenses
97.88M
273.08M
52.18M
152.32M
Net income
8.72B
5.08B
6.98B
6.75B
Net profit margin
15.52%
9.94%
13.24%
11.93%
Earnings per share
-
-
-
-
Interest and investment income
478.34M
526.28M
502.90M
548.05M
Interest expense
-722.02K
-819.90K
-321.13K
-559.74K
Net interest expenses
477.61M
525.46M
502.58M
547.49M
Depreciation and amortization charges
139.32M
140.33M
140.63M
144.78M
EBITDA
13.11B
6.50B
10.96B
11.20B
Gain or loss from assets sale
-2.00M
3.00K
-13.64M
-2.73M
AI content may include mistakes. Learn more
Google apps